495 related articles for article (PubMed ID: 22036653)
1. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of powders for inhalation: the effect of drug concentration on particle detachment.
Le VN; Hoang Thi TH; Robins E; Flament MP
Int J Pharm; 2012 Mar; 424(1-2):44-9. PubMed ID: 22207163
[TBL] [Abstract][Full Text] [Related]
3. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
4. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
5. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
Flament MP; Leterme P; Gayot A
Int J Pharm; 2004 May; 275(1-2):201-9. PubMed ID: 15081150
[TBL] [Abstract][Full Text] [Related]
6. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
Thi TH; Danède F; Descamps M; Flament MP
Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
[TBL] [Abstract][Full Text] [Related]
7. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
9. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
10. Influence of carrier on the performance of dry powder inhalers.
Saint-Lorant G; Leterme P; Gayot A; Flament MP
Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
[TBL] [Abstract][Full Text] [Related]
11. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
[TBL] [Abstract][Full Text] [Related]
12. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
Le VN; Hoang Thi TH; Robins E; Flament MP
AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285
[TBL] [Abstract][Full Text] [Related]
13. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
14. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
15. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
J Pharm Sci; 2010 Aug; 99(8):3415-29. PubMed ID: 20222025
[TBL] [Abstract][Full Text] [Related]
16. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
Hassan MS; Lau R
Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
[TBL] [Abstract][Full Text] [Related]
17. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
18. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
19. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
[TBL] [Abstract][Full Text] [Related]
20. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]